Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant eyebrow and eyelash growth after starting a hair loss treatment routine that includes oral minoxidil, oral dutasteride, topical minoxidil, Nizoral shampoo, microneedling, and supplements. They also reported positive scalp hair gains and no significant side effects.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user is using a hair loss treatment involving dutasteride, minoxidil, finasteride, microneedling, and supplements like multivitamins, D3 K2, and Omega 3 fish oil. They are considering adding tretinoin and are open to suggestions while managing gut issues.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

A 31-year-old is happy with hair regrowth and thickening after using 0.5 mg dutasteride daily and 5% topical minoxidil. Initial results appeared in six months, with continued improvement over time.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The user switched from finasteride to dutasteride for hair loss and saw significant improvement in under two months. They also microneedle, take supplements including collagen and vitamin D3, use ketoconazole shampoo, and noticed accidental hair regrowth with retinol application on their face.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The user is experiencing positive results in hair regrowth using a regimen of 0.5 mg dutasteride, 5 mg oral minoxidil, ketoconazole shampoo, microneedling, and a combination of topical minoxidil with RU58841. They report no side effects and express gratitude for the support and inspiration from the community.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

Significant hair regrowth was achieved using 0.5mg oral finasteride, a topical mix of finasteride and minoxidil, and dermastamping. Initial side effects like achy testicles were managed by adjusting the regimen.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user experienced significant hair thinning and scalp irritation after three months of using topical finasteride. Suggestions include that shedding is normal before regrowth and switching to oral finasteride or addressing scalp inflammation might help.

The conversation is about hair loss treatments, specifically the lack of improvement after one year of using oral finasteride and topical minoxidil. Suggestions include switching to stronger medications like dutasteride and oral minoxidil, considering a hair transplant, and possibly using microneedling or tretinoin.

Body hair is more resilient than scalp hair due to different gene expressions and DHT sensitivity. Treatments like minoxidil and finasteride are used for hair loss, but they have varying effects on body and scalp hair.

The user reported positive results with thicker and denser hair after four months of taking 1mg oral finasteride daily, without using minoxidil. Some users discussed potential side effects like mild testicular ache and debated the timing and benefits of adding minoxidil to the regimen.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

Minoxidil and finasteride work through different mechanisms; minoxidil-dependent hair requires continued use to maintain growth, while finasteride prevents further hair loss but cannot sustain minoxidil gains alone. Current treatments like minoxidil, finasteride, and others need indefinite use, as no permanent solution exists yet.

Minoxidil can effectively promote hair regrowth with consistent use, but results differ among individuals. Some recommend combining it with finasteride for better long-term results, though OP chooses to use only minoxidil and accepts the possibility of going bald.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

Dutasteride is more effective than finasteride for hair loss, with optimal dosing at 0.5mg once or twice a week to minimize side effects. Topical application may further reduce side effects while effectively lowering scalp DHT.

Vitamin deficiencies, particularly in vitamins A, B, C, D, and minerals like iron, zinc, and copper, can lead to hair loss. Dietary changes, such as eating more nutrient-rich foods, can improve hair health.